StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) shareholders

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.85−0.38 (-11.61%)

Close on Nov 17, 2026Market cap $234.24MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
90M of 82M shares
Institutional holders
142
28 new, 22 sold out
Net institutional buying
15M
In Q2 2026
Insider trades, 12 months
0 buys · 17 sales
Net sold $751.98K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Balyasny Asset Management L.P.
Joint filing with Bam Gp LLC (9.99%), Balyasny Asset Management Holdings LP (9.99%) and 2 more
7,844,3119.99%13G (passive) amendmentJun 30, 2026
Janus Henderson Group PLC7,291,4349.99%13G (passive) amendmentNov 28, 2025
Dmitry Balyasny
Joint filing with Bam Gp LLC (9.89%), Balyasny Asset Management Holdings LP (9.89%) and 2 more
7,221,5559.89%13G (passive) amendmentDec 31, 2025
Balyasny Asset Management Holdings LP
Joint filing with Bam Gp LLC (9.69%), Balyasny Asset Management L.P. (9.69%) and 2 more
7,176,1449.69%13G (passive) amendmentMar 31, 2026
Affinity Asset Advisors, LLC
Joint filing with Michael Cho (8.40%)
6,674,9138.40%13G (passive) amendmentJun 30, 2026
Paradigm BioCapital Advisors LP
Joint filing with Paradigm BioCapital Advisors GP LLC (8.30%), Senai Asefaw, M.D. (8.30%) and 1 more
6,184,1348.30%13G (passive) amendmentMar 31, 2026
Suvretta Capital Management, LLC
Joint filing with Aaron Cowen (7.70%), Averill Master Fund, Ltd. (6.50%)
5,674,7787.70%13G (passive)Apr 6, 2026
James N. Topper
Joint filing with Patrick J. Heron (9.90%), Albert Cha (8.30%) and 4 more
5,500,8129.90%13G (passive)May 28, 2025
Kenneth Griffin
Joint filing with Citadel Advisors Holdings LP (7.20%), Citadel Advisors LLC (7.20%) and 1 more
5,498,2197.40%13G (passive) amendmentDec 31, 2025
Bam Gp LLC
Joint filing with Balyasny Asset Management Holdings LP (9.99%), Balyasny Asset Management L.P. (9.99%) and 2 more
5,394,7219.99%13G (passive) amendmentSep 30, 2025
Michael Cho
Joint filing with Affinity Asset Advisors, LLC (7.10%)
5,217,6607.10%13G (passive) amendmentJan 22, 2026
Rajeev Shah
Joint filing with Peter Kolchinsky (6.90%), RA Capital Healthcare Fund, L.P. (6.90%) and 1 more
5,000,0006.90%13G (passive)Oct 20, 2025
BlackRock, Inc.4,885,8146.70%13G (passive)Dec 31, 2025
JPMorgan Chase & Co.4,573,7015.50%13G (passive)Sep 30, 2026
Paradigm BioCapital Advisors GP LLC
Joint filing with Paradigm BioCapital Advisors LP (5.30%), Senai Asefaw, M.D. (5.30%)
4,175,3825.30%13G (passive) amendmentJun 30, 2026
Vestal Point Capital, LP
Joint filing with Ryan Wilder (7.50%)
4,117,3027.50%13G (passive) amendmentSep 30, 2025
Frazier Life Sciences Public Fund, L.P.
Joint filing with Fhmlsp, L.L.C. (5.10%), Fhmlsp, L.P. (5.10%)
3,698,2715.10%13G (passive) amendmentDec 31, 2025
Ryan Wilder
Joint filing with Vestal Point Capital, LP (6.00%)
3,228,1616.00%13G (passive)Jun 30, 2025
Millennium Management LLC
Joint filing with Israel A. Englander (5.30%), Millennium Group Management LLC (5.30%)
2,836,2925.30%13G (passive) amendmentJun 30, 2025
Mizuho Financial Group, Inc.2,203,6316.60%13G (passive) amendmentMar 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of LXEOValueChange% of portfolio
Suvretta Capital Management, LLC6,384,2007.78%$29.72M+5,134,2000.54%
Affinity Asset Advisors, LLC5,807,6117.08%$27.03M+757,4001.22%
BlackRock, Inc.5,739,4557.00%$26.72M+628,5840.00%
Ra Capital Management, L.P.5,000,0006.09%$23.28M–0.20%
Frazier Life Sciences Management, L.P.4,824,7255.88%$22.46M+400,0000.49%
State Street Corp4,354,7575.31%$20.27M+786,5150.00%
Vestal Point Capital, LP4,320,0005.27%$20.11M−155,0000.47%
Paradigm Biocapital Advisors LP4,175,3825.09%$19.44M−2,008,7520.36%
Jupiter Topco LLC3,954,6914.82%$18.41MNew0.01%
Orbimed Advisors LLC3,947,8504.81%$18.38M+345,4000.34%
Citadel Advisors LLC3,898,5704.75%$18.15M+63,5710.00%
Vanguard Capital Management LLC3,125,8933.81%$14.55M+118,8000.00%
Millennium Management LLC2,833,6223.45%$13.19M+1,220,8420.00%
Nantahala Capital Management, LLC2,600,0003.17%$12.10M+1,400,0000.20%
Woodline Partners LP2,500,5323.05%$11.64M−250,0000.04%
Balyasny Asset Management L.P.2,412,7422.94%$11.23M+823,1570.01%
Goldman Sachs Group Inc2,149,6122.62%$10.01M+199,7270.00%
683 Capital Management, LLC1,875,0002.29%$8.73M+675,0000.43%
Geode Capital Management, LLC1,747,9592.13%$8.14M+234,1820.00%
ADAR1 Capital Management, LLC1,565,9501.91%$7.29M+98,6000.33%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202614290M100.0%28 / 5939 / 2221M7M
Q1 202613980M97.4%21 / 5838 / 2715M8M
Q4 202514676M93.2%47 / 6126 / 934M7M
Q3 202510949M60.1%26 / 5015 / 710M3M
Q2 20259042M51.5%17 / 3617 / 1519M5M
Q1 20258828M34.1%17 / 2523 / 184M6M
Q4 20249030M36.0%29 / 2912 / 84M4M
Q3 20246930M36.4%16 / 369 / 68M4M
Q2 20246027M32.4%15 / 2713 / 95M1M
Q1 20245423M28.2%28 / 185 / 57M0M
Q4 20233116M19.7%31 / 00 / 016M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

138 funds held LXEO in Q2 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of LXEOValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF2,429,5922.96%$11.31M0.11%Jun 30, 2026
Vanguard Total Stock Market Index Fund2,335,1442.85%$10.87M0.00%Jun 30, 2026
iShares Russell 2000 ETF1,846,0162.25%$8.59M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund776,5290.95%$3.21M0.01%Jul 31, 2026
Vanguard Extended Market Index Fund715,4130.87%$3.33M0.00%Jun 30, 2026
iShares Russell 2000 Value ETF665,3260.81%$3.10M0.02%Jun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF566,2000.69%$2.64M0.09%Jun 30, 2026
Janus Henderson Global Life Sciences Fund561,2640.68%$2.61M0.04%Jun 30, 2026
iShares Biotechnology ETF435,0530.53%$2.03M0.02%Jun 30, 2026
Vanguard Russell 2000 Index Fund339,1140.41%$1.74M0.01%May 31, 2026
Fidelity Extended Market Index Fund308,0020.38%$1.58M0.00%May 31, 2026
Small Cap Value Fund261,1090.32%$1.22M0.18%Jun 30, 2026
Dimensional U.S. Small Cap ETF254,0510.31%$1.05M0.01%Jul 31, 2026
iShares Micro-Cap ETF238,2490.29%$1.11M0.07%Jun 30, 2026
U.S. Small Cap Portfolio232,1320.28%$958.71K0.00%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Richard Nolan TownsendChief Executive Officer, Director376,7780.46%Sep 28, 2026
Narinder Pal BhallaChief Medical Officer84,9080.10%Sep 28, 2026
Jose Manuel OteroChief Operating Officer138,2880.17%Sep 28, 2026
Louis Edward TamayoChief Financial Officer92,9070.11%Sep 28, 2026
Eric AdlerChief Medical Officer72,6460.09%Nov 20, 2025
Jenny RobertsonChief Legal Officer68,3810.08%Nov 20, 2025
Tai Sandi SeeChief Development Officer65,4760.08%Nov 20, 2025
Kyle RasbachChief Financial Officer40,8750.05%Jan 22, 2025
Tobin SchilkeDirector––Nov 17, 2026
Brenda CooperstoneDirector––Jun 29, 2026
Tolga TangulerDirector––Jun 29, 2026
Mette Kirstine AggerDirector––Jun 29, 2026
Reinaldo M. DiazDirector––Jun 29, 2026
Paula H. CholmondeleyDirector30,6270.04%Jun 29, 2026
Hauwermeiren Timothy VanDirector––Jun 29, 2026
Steven AltschulerDirector––Jun 29, 2026
Laura Sepp-LorenzinoDirector––Apr 30, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jose Manuel Otero
Chief Operating Officer
Sep 14, 2026Award+2,110$2.64$5.57K138,288
Narinder Pal Bhalla
Chief Medical Officer
Sep 14, 2026Award+2,714$3.58$9.72K84,908
Richard Nolan Townsend
Chief Executive Officer, Director
Sep 14, 2026Award+2,306$2.64$6.09K376,778
Louis Edward Tamayo
Chief Financial Officer
Aug 18, 2026Sale−4,117$4.91$20.21K92,907
Jose Manuel Otero
Chief Operating Officer
Aug 18, 2026Sale−1,304$4.96$6.47K136,178
Richard Nolan Townsend
Chief Executive Officer, Director
Aug 18, 2026Sale−3,345$4.95$16.56K374,472
Richard Nolan Townsend
Chief Executive Officer, Director
Jul 1, 2026Sale−25,947$4.48$116.24K377,817
Louis Edward Tamayo
Chief Financial Officer
Jul 1, 2026Sale−4,641$4.49$20.84K97,024
Narinder Pal Bhalla
Chief Medical Officer
Jul 1, 2026Sale−22,306$4.42$98.59K82,194
Jose Manuel Otero
Chief Operating Officer
Jul 1, 2026Sale−4,666$4.48$20.90K137,482
Richard Nolan Townsend
Chief Executive Officer, Director
Jun 29, 2026Award+67,000––403,764
Louis Edward Tamayo
Chief Financial Officer
Jun 29, 2026Award+12,000––101,665
Narinder Pal Bhalla
Chief Medical Officer
Jun 29, 2026Award+55,000––104,500
Jose Manuel Otero
Chief Operating Officer
Jun 29, 2026Award+12,060––142,148
Richard Nolan Townsend
Chief Executive Officer, Director
May 18, 2026Sale−3,342$5.06$16.91K336,764
Jose Manuel Otero
Chief Operating Officer
May 18, 2026Sale−1,302$5.07$6.60K130,088
Richard Nolan Townsend
Chief Executive Officer, Director
Apr 6, 2026Sale(10b5-1 plan)−55,000$5.69$312.95K340,106
Richard Nolan Townsend
Chief Executive Officer, Director
Mar 13, 2026Award+2,623$2.64$6.92K395,106
Jose Manuel Otero
Chief Operating Officer
Mar 13, 2026Award+5,930$2.64$15.66K131,390
Jose Manuel Otero
Chief Operating Officer
Feb 18, 2026Sale−3,016$6.40$19.30K125,460
Richard Nolan Townsend
Chief Executive Officer, Director
Feb 18, 2026Sale−10,173$6.38$64.90K392,483
Narinder Pal Bhalla
Chief Medical Officer
Feb 13, 2026Award+49,500––49,500
Louis Edward Tamayo
Chief Financial Officer
Feb 4, 2026Award+44,665––89,665
Richard Nolan Townsend
Chief Executive Officer, Director
Feb 4, 2026Award+161,665––402,656
Jose Manuel Otero
Chief Operating Officer
Feb 4, 2026Award+65,000––128,476
Jose Manuel Otero
Chief Operating Officer
Nov 18, 2025Sale−721$9.27$6.68K63,476
Tai Sandi See
Chief Development Officer
Nov 18, 2025Sale−386$9.27$3.58K65,476
Eric Adler
Chief Medical Officer
Nov 18, 2025Sale−615$9.27$5.70K72,646
Richard Nolan Townsend
Chief Executive Officer, Director
Nov 18, 2025Sale−1,127$9.27$10.45K240,991
Jenny Robertson
Chief Legal Officer
Nov 18, 2025Sale−549$9.27$5.09K68,381
Eric Adler
Chief Medical Officer
Oct 17, 2025Sale−3,344$8.94$29.90K73,299
Eric Adler
Chief Medical Officer
Oct 17, 2025Sale−38$9.56$36373,261
Tai Sandi See
Chief Development Officer
Oct 17, 2025Sale−3,844$8.94$34.37K65,906
Tai Sandi See
Chief Development Officer
Oct 17, 2025Sale−44$9.56$42165,862
Jose Manuel Otero
Chief Technical Officer
Oct 17, 2025Sale−24$9.56$22964,197
Jose Manuel Otero
Chief Technical Officer
Oct 17, 2025Sale−2,091$8.94$18.69K64,221
Richard Nolan Townsend
Chief Executive Officer, Director
Oct 17, 2025Sale−148$9.56$1.41K242,118
Richard Nolan Townsend
Chief Executive Officer, Director
Oct 17, 2025Sale−12,985$8.94$116.09K242,266
Jenny Robertson
Chief Legal Officer
Oct 17, 2025Sale−3,486$8.94$31.16K68,970
Jenny Robertson
Chief Legal Officer
Oct 17, 2025Sale−40$9.56$38268,930
Eric Adler
Chief Medical Officer
Oct 15, 2025Award+9,570––76,643
Tai Sandi See
Chief Development Officer
Oct 15, 2025Award+10,890––69,750
Jose Manuel Otero
Chief Technical Officer
Oct 15, 2025Award+5,940––66,312
Richard Nolan Townsend
Chief Executive Officer, Director
Oct 15, 2025Award+33,000––255,251
Jenny Robertson
Chief Legal Officer
Oct 15, 2025Award+9,900––72,456
Richard Nolan Townsend
Chief Executive Officer, Director
Sep 12, 2025Award+2,193$2.64$5.79K222,251
Louis Edward Tamayo
Chief Financial Officer
Aug 29, 2025Award+45,000––45,000
Jose Manuel Otero
Chief Technical Officer
Aug 18, 2025Sale−721$9.27$6.68K63,476
Richard Nolan Townsend
Chief Executive Officer, Director
Aug 18, 2025Sale−1,115$4.67$5.21K220,058
Tai Sandi See
Chief Development Officer
Aug 18, 2025Sale−382$4.67$1.78K58,860
Richard Nolan Townsend
Chief Executive Officer, Director
Aug 18, 2025Sale−2,735$4.67$12.77K220,058
Jose Manuel Otero
Chief Technical Officer
Aug 18, 2025Sale−2,848$4.67$13.30K60,372
Jenny Robertson
Chief Legal Officer
Aug 18, 2025Sale−542$4.67$2.53K62,556
Eric Adler
Chief Medical Officer
Aug 18, 2025Sale−608$4.67$2.84K67,073
Eric Adler
Chief Medical Officer
May 16, 2025Sale−585$2.77$1.62K67,681
Jenny Robertson
Chief Legal Officer
May 16, 2025Sale−521$2.77$1.44K63,098
Richard Nolan Townsend
Chief Executive Officer, Director
May 16, 2025Sale−1,074$2.77$2.97K221,173
Tai Sandi See
Chief Development Officer
May 16, 2025Sale−367$2.77$1.02K59,242
Jose Manuel Otero
Chief Technical Officer
Mar 14, 2025Award+5,720$2.61$14.93K63,220
Jenny Robertson
Chief Legal Officer
Mar 14, 2025Award+5,720$2.61$14.93K63,619

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
21.01%
17M shares short
Days to cover
12.7
At 1M shares a day
Change since last report
-2.9%
From 18M shares
Short volume, 20 days
48.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lexeo Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,471 shares on Oct 13, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Richard Nolan Townsend
Officer, Director
Aug 18, 20263,345$16.56KAug 18, 2026Restricted Stock Vesting
Jose Manuel Otero
Officer
Aug 18, 20261,304$6.46KAug 18, 2026Restricted Stock Vesting
Louis Edward Tamayo
Officer
Aug 18, 20264,117$20.20KAug 18, 2026Restricted Stock Vesting
Richard Nolan Townsend
Officer, Director
Jul 1, 202625,947$116.19KJul 1, 2026Restricted Stock Vesting
Narinder Pal Bhalla
Officer
Jul 1, 202622,306$98.68KJul 1, 2026Restricted Stock Vesting
Louis Edward Tamayo
Officer
Jul 1, 20264,641$20.81KJul 1, 2026Restricted Stock Vesting
Jose Manuel Otero
Officer
Jul 1, 20264,666$20.92KJul 1, 2026Restricted Stock Vesting
Richard Nolan Townsend
Officer, Director
May 18, 20263,342$16.93KMay 18, 2026Restricted Stock Vesting
Jose Manuel Otero
Officer
May 18, 20261,302$6.61KMay 18, 2026Restricted Stock Vesting
Eric Adler
Officer
May 18, 20261,595$8.07KMay 18, 2026Restricted Stock Vesting
Richard Nolan Townsend
Director, Officer
Apr 6, 202655,000$314.60KApr 6, 2026CS-3 Incentive Units
Tai Sandi See
Officer
Feb 18, 20263,861$24.68KFeb 18, 2026Restricted Stock Vesting
Richard Nolan Townsend
Officer, Director
Feb 18, 202611,374$72.59KFeb 18, 2026Restricted Stock Vesting
Eric Adler
Officer
Feb 18, 20264,867$31.14KFeb 18, 2026Restricted Stock Vesting
Jenny Robertson
Officer
Feb 18, 20263,736$23.90KFeb 18, 2026Restricted Stock Vesting

See a number that looks wrong?